{"id":22321,"date":"2024-01-30T08:47:47","date_gmt":"2024-01-30T07:47:47","guid":{"rendered":"https:\/\/ggba.swiss\/onward-therapeutics-enters-clinical-phase-with-innovative-cancer-immunotherapy\/"},"modified":"2024-01-30T08:51:15","modified_gmt":"2024-01-30T07:51:15","slug":"onward-therapeutics-entame-la-phase-clinique-de-son-immunotherapie-anticancereuse-innovante","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/fr\/onward-therapeutics-entame-la-phase-clinique-de-son-immunotherapie-anticancereuse-innovante\/","title":{"rendered":"Onward Therapeutics entame la phase clinique de son immunoth\u00e9rapie anticanc\u00e9reuse innovante"},"content":{"rendered":"\n<p>En f\u00e9vrier 2021, <a href=\"https:\/\/www.onward-therapeutics.com\/\">Onward Therapeutics<\/a> a obtenu de <a href=\"https:\/\/www.biomunex.com\/\">Biomunex Pharmaceuticals<\/a> les droits mondiaux exclusifs pour le d\u00e9veloppement, la fabrication et la commercialisation d&rsquo;OT-A201. Cette collaboration implique le co-d\u00e9veloppement de l&rsquo;anticorps bisp\u00e9cifique jusqu&rsquo;\u00e0 l&rsquo;ach\u00e8vement de l&rsquo;\u00e9tude de phase 1. OT-A201, un anticorps bisp\u00e9cifique humanis\u00e9, premier de sa cat\u00e9gorie, cible deux points de contr\u00f4le immunitaire, ce qui repr\u00e9sente un immense potentiel pour le traitement des h\u00e9mopathies malignes avanc\u00e9es et des tumeurs solides.<\/p>\n\n\n\n<p>Les \u00e9tudes pr\u00e9cliniques d&rsquo;OT-A201 ont donn\u00e9 des r\u00e9sultats prometteurs, montrant une excellente r\u00e9activit\u00e9, une grande s\u00e9curit\u00e9 et des activit\u00e9s anti-tumorales notables \u00e0 diff\u00e9rentes doses. Cet anticorps, bas\u00e9 sur la technologie BiXAb de Biomunex, pr\u00e9sente \u00e9galement un champ Fc fonctionnel qui contribue \u00e0 l&rsquo;activit\u00e9 ADCC contre les cellules tumorales, affichant des propri\u00e9t\u00e9s telles qu&rsquo;un bon appariement, une faible agr\u00e9gation et une grande stabilit\u00e9.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\">Faire progresser les projets innovants dans la lutte contre le cancer<\/h4>\n\n\n\n<p>L&rsquo;\u00e9tude multicentrique europ\u00e9enne n\u00b0 A20101, r\u00e9cemment lanc\u00e9e, vise \u00e0 \u00e9valuer la s\u00e9curit\u00e9, la tol\u00e9rabilit\u00e9, la pharmacocin\u00e9tique et l&rsquo;efficacit\u00e9 anti-tumorale pr\u00e9liminaire d&rsquo;OT-A201. Cette \u00e9tude ouverte comprend deux parties : une phase de mont\u00e9e en dose pour les patients atteints de tumeurs h\u00e9matologiques malignes sp\u00e9cifiques r\u00e9currentes\/r\u00e9fractaires ou de tumeurs solides avanc\u00e9es\/m\u00e9tastatiques, et une phase d&rsquo;expansion pour \u00e9valuer davantage la s\u00e9curit\u00e9 et l&rsquo;efficacit\u00e9 de l&rsquo;anticorps en monoth\u00e9rapie ou en combinaison dans des conditions d\u00e9finies.<\/p>\n\n\n\n<p>Le traitement du premier patient a donn\u00e9 lieu \u00e0 un accord de paiement d&rsquo;\u00e9tape non divulgu\u00e9 \u00e0 Biomunex, marquant un progr\u00e8s dans la d\u00e9marche d&rsquo;Onward Therapeutics. Le Dr C. Grace Yeh, CEO d&rsquo;Onward Therapeutics, a exprim\u00e9 son enthousiasme \u00e0 l&rsquo;id\u00e9e de tester OT-A201 sur des patients, soulignant l&rsquo;efficacit\u00e9 de l&rsquo;entreprise \u00e0 passer du d\u00e9veloppement de la lign\u00e9e cellulaire \u00e0 la fabrication \u00e0 grande \u00e9chelle et aux \u00e9tudes pr\u00e9cliniques. La d\u00e9claration de Dr. Yeh souligne l&rsquo;engagement de l&rsquo;entreprise \u00e0 l&rsquo;\u00e9gard de son business model \u00ab&nbsp;buy-to-build&nbsp;\u00bb et marque une \u00e9tape cruciale dans la transition d&rsquo;Onward Therapeutics vers une entreprise de stade clinique.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Bas\u00e9e au Biop\u00f4le \u00e0 Lausanne, Onward Therapeutics a fait un bond significatif dans le domaine de la biotechnologie en lan\u00e7ant l&rsquo;essai clinique de phase 1 d&rsquo;OT-A201, son anticorps bisp\u00e9cifique pionnier. <\/p>\n","protected":false},"author":6,"featured_media":22318,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[843],"tags":[1169,1140,1141,1168],"class_list":["post-22321","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sciences-de-la-vie","tag-biotech-fr-2","tag-oncology-fr-2","tag-personalized-medicine-fr-2","tag-technology-park-fr-2"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>L&#039;immunoth\u00e9rapie anticanc\u00e9reuse d&#039;Onward en phase clinique<\/title>\n<meta name=\"description\" content=\"Bas\u00e9e au Biop\u00f4le de Lausanne, Onward Therapeutics a lanc\u00e9 l&#039;essai clinique de phase 1 de OT-A201, son anticorps pionnier.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ggba.swiss\/fr\/onward-therapeutics-entame-la-phase-clinique-de-son-immunotherapie-anticancereuse-innovante\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"L&#039;immunoth\u00e9rapie anticanc\u00e9reuse d&#039;Onward en phase clinique\" \/>\n<meta property=\"og:description\" content=\"Bas\u00e9e au Biop\u00f4le de Lausanne, Onward Therapeutics a lanc\u00e9 l&#039;essai clinique de phase 1 de OT-A201, son anticorps pionnier.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ggba.swiss\/fr\/onward-therapeutics-entame-la-phase-clinique-de-son-immunotherapie-anticancereuse-innovante\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2024-01-30T07:47:47+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-01-30T07:51:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ggba.swiss\/app\/uploads\/2024\/01\/Onward-Therapeutics-Cancer-Treatment-1024x704.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"704\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Pierre-Yves Oehrli\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pierre-Yves Oehrli\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ggba.swiss\/fr\/onward-therapeutics-entame-la-phase-clinique-de-son-immunotherapie-anticancereuse-innovante\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/onward-therapeutics-entame-la-phase-clinique-de-son-immunotherapie-anticancereuse-innovante\/\"},\"author\":{\"name\":\"Pierre-Yves Oehrli\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"headline\":\"Onward Therapeutics entame la phase clinique de son immunoth\u00e9rapie anticanc\u00e9reuse innovante\",\"datePublished\":\"2024-01-30T07:47:47+00:00\",\"dateModified\":\"2024-01-30T07:51:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/onward-therapeutics-entame-la-phase-clinique-de-son-immunotherapie-anticancereuse-innovante\/\"},\"wordCount\":386,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/onward-therapeutics-entame-la-phase-clinique-de-son-immunotherapie-anticancereuse-innovante\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/01\/Onward-Therapeutics-Cancer-Treatment.jpeg\",\"keywords\":[\"Biotech\",\"Oncology\",\"Personalized Medicine\",\"Technology Park\"],\"articleSection\":[\"Sciences de la vie\"],\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ggba.swiss\/fr\/onward-therapeutics-entame-la-phase-clinique-de-son-immunotherapie-anticancereuse-innovante\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ggba.swiss\/fr\/onward-therapeutics-entame-la-phase-clinique-de-son-immunotherapie-anticancereuse-innovante\/\",\"url\":\"https:\/\/ggba.swiss\/fr\/onward-therapeutics-entame-la-phase-clinique-de-son-immunotherapie-anticancereuse-innovante\/\",\"name\":\"L'immunoth\u00e9rapie anticanc\u00e9reuse d'Onward en phase clinique\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/onward-therapeutics-entame-la-phase-clinique-de-son-immunotherapie-anticancereuse-innovante\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/onward-therapeutics-entame-la-phase-clinique-de-son-immunotherapie-anticancereuse-innovante\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/01\/Onward-Therapeutics-Cancer-Treatment.jpeg\",\"datePublished\":\"2024-01-30T07:47:47+00:00\",\"dateModified\":\"2024-01-30T07:51:15+00:00\",\"author\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"description\":\"Bas\u00e9e au Biop\u00f4le de Lausanne, Onward Therapeutics a lanc\u00e9 l'essai clinique de phase 1 de OT-A201, son anticorps pionnier.\",\"breadcrumb\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/onward-therapeutics-entame-la-phase-clinique-de-son-immunotherapie-anticancereuse-innovante\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ggba.swiss\/fr\/onward-therapeutics-entame-la-phase-clinique-de-son-immunotherapie-anticancereuse-innovante\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ggba.swiss\/fr\/onward-therapeutics-entame-la-phase-clinique-de-son-immunotherapie-anticancereuse-innovante\/#primaryimage\",\"url\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/01\/Onward-Therapeutics-Cancer-Treatment.jpeg\",\"contentUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/01\/Onward-Therapeutics-Cancer-Treatment.jpeg\",\"width\":2360,\"height\":1622,\"caption\":\"L'initiative d'Onward Therapeutics marque une transition cruciale pour l'entreprise vers la phase clinique, consolidant son r\u00f4le dans le d\u00e9veloppement de traitements innovants contre le cancer.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ggba.swiss\/fr\/onward-therapeutics-entame-la-phase-clinique-de-son-immunotherapie-anticancereuse-innovante\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ggba.swiss\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Onward Therapeutics entame la phase clinique de son immunoth\u00e9rapie anticanc\u00e9reuse innovante\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\",\"name\":\"Pierre-Yves Oehrli\",\"url\":\"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"L'immunoth\u00e9rapie anticanc\u00e9reuse d'Onward en phase clinique","description":"Bas\u00e9e au Biop\u00f4le de Lausanne, Onward Therapeutics a lanc\u00e9 l'essai clinique de phase 1 de OT-A201, son anticorps pionnier.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ggba.swiss\/fr\/onward-therapeutics-entame-la-phase-clinique-de-son-immunotherapie-anticancereuse-innovante\/","og_locale":"fr_FR","og_type":"article","og_title":"L'immunoth\u00e9rapie anticanc\u00e9reuse d'Onward en phase clinique","og_description":"Bas\u00e9e au Biop\u00f4le de Lausanne, Onward Therapeutics a lanc\u00e9 l'essai clinique de phase 1 de OT-A201, son anticorps pionnier.","og_url":"https:\/\/ggba.swiss\/fr\/onward-therapeutics-entame-la-phase-clinique-de-son-immunotherapie-anticancereuse-innovante\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2024-01-30T07:47:47+00:00","article_modified_time":"2024-01-30T07:51:15+00:00","og_image":[{"width":1024,"height":704,"url":"https:\/\/ggba.swiss\/app\/uploads\/2024\/01\/Onward-Therapeutics-Cancer-Treatment-1024x704.jpeg","type":"image\/jpeg"}],"author":"Pierre-Yves Oehrli","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Pierre-Yves Oehrli","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ggba.swiss\/fr\/onward-therapeutics-entame-la-phase-clinique-de-son-immunotherapie-anticancereuse-innovante\/#article","isPartOf":{"@id":"https:\/\/ggba.swiss\/fr\/onward-therapeutics-entame-la-phase-clinique-de-son-immunotherapie-anticancereuse-innovante\/"},"author":{"name":"Pierre-Yves Oehrli","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"headline":"Onward Therapeutics entame la phase clinique de son immunoth\u00e9rapie anticanc\u00e9reuse innovante","datePublished":"2024-01-30T07:47:47+00:00","dateModified":"2024-01-30T07:51:15+00:00","mainEntityOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/onward-therapeutics-entame-la-phase-clinique-de-son-immunotherapie-anticancereuse-innovante\/"},"wordCount":386,"commentCount":0,"image":{"@id":"https:\/\/ggba.swiss\/fr\/onward-therapeutics-entame-la-phase-clinique-de-son-immunotherapie-anticancereuse-innovante\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2024\/01\/Onward-Therapeutics-Cancer-Treatment.jpeg","keywords":["Biotech","Oncology","Personalized Medicine","Technology Park"],"articleSection":["Sciences de la vie"],"inLanguage":"fr-FR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ggba.swiss\/fr\/onward-therapeutics-entame-la-phase-clinique-de-son-immunotherapie-anticancereuse-innovante\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ggba.swiss\/fr\/onward-therapeutics-entame-la-phase-clinique-de-son-immunotherapie-anticancereuse-innovante\/","url":"https:\/\/ggba.swiss\/fr\/onward-therapeutics-entame-la-phase-clinique-de-son-immunotherapie-anticancereuse-innovante\/","name":"L'immunoth\u00e9rapie anticanc\u00e9reuse d'Onward en phase clinique","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/onward-therapeutics-entame-la-phase-clinique-de-son-immunotherapie-anticancereuse-innovante\/#primaryimage"},"image":{"@id":"https:\/\/ggba.swiss\/fr\/onward-therapeutics-entame-la-phase-clinique-de-son-immunotherapie-anticancereuse-innovante\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2024\/01\/Onward-Therapeutics-Cancer-Treatment.jpeg","datePublished":"2024-01-30T07:47:47+00:00","dateModified":"2024-01-30T07:51:15+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"description":"Bas\u00e9e au Biop\u00f4le de Lausanne, Onward Therapeutics a lanc\u00e9 l'essai clinique de phase 1 de OT-A201, son anticorps pionnier.","breadcrumb":{"@id":"https:\/\/ggba.swiss\/fr\/onward-therapeutics-entame-la-phase-clinique-de-son-immunotherapie-anticancereuse-innovante\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ggba.swiss\/fr\/onward-therapeutics-entame-la-phase-clinique-de-son-immunotherapie-anticancereuse-innovante\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ggba.swiss\/fr\/onward-therapeutics-entame-la-phase-clinique-de-son-immunotherapie-anticancereuse-innovante\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2024\/01\/Onward-Therapeutics-Cancer-Treatment.jpeg","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2024\/01\/Onward-Therapeutics-Cancer-Treatment.jpeg","width":2360,"height":1622,"caption":"L'initiative d'Onward Therapeutics marque une transition cruciale pour l'entreprise vers la phase clinique, consolidant son r\u00f4le dans le d\u00e9veloppement de traitements innovants contre le cancer."},{"@type":"BreadcrumbList","@id":"https:\/\/ggba.swiss\/fr\/onward-therapeutics-entame-la-phase-clinique-de-son-immunotherapie-anticancereuse-innovante\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/fr\/"},{"@type":"ListItem","position":2,"name":"Onward Therapeutics entame la phase clinique de son immunoth\u00e9rapie anticanc\u00e9reuse innovante"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41","name":"Pierre-Yves Oehrli","url":"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/22321","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/comments?post=22321"}],"version-history":[{"count":1,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/22321\/revisions"}],"predecessor-version":[{"id":22323,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/22321\/revisions\/22323"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media\/22318"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media?parent=22321"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/categories?post=22321"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/tags?post=22321"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}